Livedoid vasculitis - Livedoidná Vaskulitída
Livedoidná Vaskulitída (Livedoid vasculitis) je chronické kožné ochorenie, ktoré sa vyskytuje prevažne u žien v mladom až strednom veku. Jedna skratka používaná na opis jej znakov je „Bolestivé purpurové vredy s retikulárnym vzorom dolných končatín“ (PURPLE). Je spojená s množstvom ochorení, vrátane chronickej venóznej hypertenzie a varixov.
☆ Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Môže to byť sprevádzané bolesťou.
References
Livedoid vasculopathy je zriedkavé ochorenie kože charakterizované bolestivými vredmi, ktoré sa neustále vracajú na dolných končatinách.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy je zriedkavé kožné ochorenie, ktoré spôsobuje opakujúce sa vredy na dolných končatinách, ktoré za sebou zanechávajú svetlé jazvy známe ako atrophie blanche. Zatiaľ čo presná príčina je stále nejasná, predpokladá sa, že hlavným faktorom je zvýšená zrážanlivosť krvi (hypercoagulability) , pričom zápal hrá sekundárnu úlohu. Medzi faktory prispievajúce k zrážaniu krvi patria nasledujúce faktory - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Pri biopsiách stav ukazuje krvné zrazeniny vo vnútri ciev, zhrubnutie cievnych stien a zjazvenie. Liečba zahŕňa mnohostranný prístup zameraný na prevenciu krvných zrazenín pomocou liekov, ako sú protidoštičkové lieky, riedidlá krvi a fibrinolytická liečba. Na tento stav kože sa môžu použiť rôzne lieky - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy je zriedkavý stav, pri ktorom sa lézie vyskytujú na oboch nohách. Predpokladá sa, že tvorba krvných zrazenín v malých krvných cievach je spôsobená zvýšenou zrážanlivosťou a zníženým rozpadom zrazenín spolu s poškodením cievnej výstelky. Vyskytuje sa častejšie u žien, najmä vo veku 15 až 50 rokov. Účinné bolo prestať fajčiť, starať sa o rany a používať lieky, ako sú lieky na riedenie krvi a protidoštičkové lieky.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
